Trial Profile
A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Jun 2015
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Optic neuritis
- Focus Therapeutic Use
- Sponsors Novartis
- 03 May 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 04 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Feb 2014 New trial record